Reason: Marketed Without an Approved NDA/ANDA: Products found to contain undeclared sibutramine, N-Desmethylsibutramine, and N-di- Desmethylsibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.
Distributed: Products were sold to distributors nationwide. Recalling firm sold some product directly to consumers.Reason: Marketed Without an Approved NDA/ANDA: Products found to contain undeclared sibutramine, N-Desmethylsibutramine, and N-di- Desmethylsibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.
Distributed: Products were sold to distributors nationwide. Recalling firm sold some product directly to consumers.Reason: Marketed Without an Approved NDA/ANDA: Products found to contain undeclared sibutramine, N-Desmethylsibutramine, and N-di- Desmethylsibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.
Distributed: Products were sold to distributors nationwide. Recalling firm sold some product directly to consumers.Reason: Marketed Without an Approved NDA/ANDA: Products found to contain undeclared sibutramine, N-Desmethylsibutramine, and N-di- Desmethylsibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.
Distributed: Products were sold to distributors nationwide. Recalling firm sold some product directly to consumers.Reason: Marketed Without an Approved NDA/ANDA: Products found to contain undeclared sibutramine, N-Desmethylsibutramine, and N-di- Desmethylsibutramine. Sibutramine was removed from the U.S. market for safety reasons, making these products unapproved new drugs.
Distributed: Products were sold to distributors nationwide. Recalling firm sold some product directly to consumers.Reason: Presence of Foreign Tablets/Capsules: A Pharmacist reported that a bottle of Effexor XR 150 mg capsules contained a single peach colored capsule printed TKN250 which was identified as a Tikosyn (dofetilide) capsule.
Distributed: Nationwide and Puerto RicoReason: Marketed without an Approved NDA/ANDA; FDA analysis found the product to contain Chlorzoxazone, Nefopam, Diclofenac, Ibuprofen, Naproxen, and Indomethacin
Distributed: NationwideReason: Presence of Particulate Matter: During a review of retain samples, the firm found a glass particulate in one lot of Acetylcysteine Solution
Distributed: Nationwide.Reason: Failed Impurities/Degradation Specifications: High out of specification impurity test results were obtained during stability testing.
Distributed: Nationwide and Puerto RicoReason: Failed Impurities/Degradation Specifications: High out of specification impurity test results were obtained during stability testing.
Distributed: Nationwide and Puerto Rico